Categories: News

Recent Alimera Data Featured in Scientific Programming at Upcoming Annual Congress

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Follow up ILUVIEN® PALADIN data to be presented onsite at the annual Association for Research in Vision and Ophthalmology (ARVO) conference

ATLANTA, April 28, 2022 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced today that ILUVIEN® will be highlighted in various scientific abstracts at the annual Association for Research in Vision and Ophthalmology (ARVO) conference being held in Denver, Colorado from May 1-4 and virtually May 11-12, 2022.

Key ILUVIEN Abstracts:

Presentation

Posters

  • David Dyer, MD, Three Year Outcomes from the PALADIN Phase IV Study: Distribution of Intraocular Pressure Outcomes by Patient Subgroup
  • Ramin Khoramnia, MD, Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): Final study results from the European IRISS registry study.

ARVO is among the largest vision research meetings held annually in the field of ophthalmology. Annual meeting educational content is planned by the ARVO program committee, and ARVO does not endorse, promote, approve or recommend the use of any products, devices or services.

About PALADIN
The PALADIN study was a phase 4, open-label, prospective, observational study conducted over 36 months at 41 sites across the United States. This study was designed and developed to confirm the benefit of using a prior course of corticosteroid as indicated in the ILUVIEN U.S. label, to mitigate the risk of uncontrolled IOP elevation. Researchers enrolled 202 eyes in 159 patients with DME who had previously received corticosteroid treatment without a clinically significant rise in IOP. All eyes were treated with ILUVIEN and patients were followed for up to 36 months. Additionally, secondary outcomes confirmed improvement in vision and reduction in treatment burden and retinal thickness variability.

About IRISS
The IRISS study was a phase 4 study designed to assess the long-term safety and effectiveness of the fluocinolone acetonide (FAc) implant in all indications in real-world practices in Europe. Six-hundred-and-ninety-five eyes from 556 patients were treated with the FAc implant. Patients receiving FAc implants between 2013 and 2017 were included and monitored until the last patient reached ≥3 years of follow-up. Study included data collected prospectively and retrospectively (51.6% and 48.4%, respectively). Other outcomes included mean intraocular pressure data over time, IOP events, use of IOP-lowering therapy, mean change in visual acuity, and supplemental therapy use among others.

About Alimera
Alimera is a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.

For press inquiries:
Cassy Dump
for Alimera
619-971-1887
cassy.dump@precisionvh.com
For investor inquiries:
Scott Gordon
for Alimera
scottg@coreir.com

Staff

Recent Posts

Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer

Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Basal Cell Carcinoma…

44 minutes ago

Glow Lifetech Provides Commercial Update; Expands to 1000+ Stores in Ontario and Achieves #2 Oil Brand with MOD

Toronto, Ontario--(Newsfile Corp. - June 23, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…

44 minutes ago

FinThrive Introduces Agentic AI at HFMA 2025 to Help Customers Transform Healthcare Revenue Cycle Management Performance

Company to also highlight advancements in denials and underpayments management and speak to the measurable…

21 hours ago

FinThrive Debuts Denials and Underpayments Analyzer, a Unified Solution for Denials and Underpayments, at HFMA 2025

Next generation analyzer helps hospitals protect revenue before it's lost by delivering timely end-to-end visibility…

21 hours ago

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine

Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed mean weight reduction…

24 hours ago